Han Xi Qin, Pang Yu, Ma Yan, Liu Yu Hong, Guo Ru, Shu Wei, Huang Xue Rui, Ge Qi Ping, DU Jian, Gao Wei Wei
Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
Biomed Environ Sci. 2017 Feb;30(2):139-142. doi: 10.3967/bes2017.018.
We assessed the incidence of adverse drug reactions (ADRs) with anti-TB medications and evaluated the risk factors for developing ADRs in previously treated tuberculosis patients in China. All patients received the first-line anti-TB regimen (2HREZS/6HRE) as recommended by the national guidelines. Clinical and laboratory evaluations were performed once a month. Out of the 354 participants, 262 (74.0%) experienced ADRs such as hyperuricemia (65.0%, 230/354), hepatotoxicity (6.2%, 22/354) and hearing disturbances (4.8%, 17/354). ADRs were significantly associated with diabetes mellitus [OR (95% CI): 15.5 (2.07-115.87)]; however, weight more than 50 kg [OR (95% CI): 0.41 (0.22-0.85)] was a protective factor for occurrence of ADRs. Hyperuricemia is the most common adverse event but, most patients with hyperuricemia showed increased tolerance for high uric acid levels. Low body weight and diabetes mellitus increased the risk of the occurrence of ADRs during anti-TB treatment.
我们评估了抗结核药物的药物不良反应(ADR)发生率,并评估了中国既往治疗的结核病患者发生ADR的危险因素。所有患者均按照国家指南推荐接受一线抗结核治疗方案(2HREZS/6HRE)。每月进行一次临床和实验室评估。在354名参与者中,262名(74.0%)出现了ADR,如高尿酸血症(65.0%,230/354)、肝毒性(6.2%,22/354)和听力障碍(4.8%,17/354)。ADR与糖尿病显著相关[比值比(95%置信区间):15.5(2.07-115.87)];然而,体重超过50 kg[比值比(95%置信区间):0.41(0.22-0.85)]是ADR发生的保护因素。高尿酸血症是最常见的不良事件,但大多数高尿酸血症患者对高尿酸水平的耐受性增加。低体重和糖尿病增加了抗结核治疗期间发生ADR的风险。